# Whole-Genome Sequencing Reveals a Novel GATA2 Mutation in Lower-Grade Glioma: Bioinformatics Analysis of Functional and Therapeutic Implications

## TL;DR

A new GATA2 mutation in lower-grade glioma was found using whole-genome sequencing, and it may affect drug binding and treatment effectiveness.

## Contribution

The study identifies and analyzes a novel GATA2 p.Arg396Trp mutation in lower-grade glioma with potential therapeutic implications.

## Key findings

- The GATA2 p.Arg396Trp mutation is predicted to be pathogenic and disrupt protein function.
- The mutation may alter drug binding dynamics, affecting treatment response in glioma patients.
- GATA2 is suggested as a potential biomarker for precision medicine in lower-grade gliomas.

## Abstract

Lower-grade gliomas represent a distinct molecular subtype of brain tumors with unique therapeutic challenges. This study investigates a novel genetic mutation, p.Arg396Trp, in the GATA2 gene, identified in an IDH-mutant astrocytoma patient through whole-genome sequencing. Using comprehensive computational methods, we examined how this mutation affects protein structure and interaction with cancer drugs. Our findings suggest that the mutation is pathogenic and may alter drug binding, potentially influencing treatment effectiveness. This research highlights the importance of genetic screening in lower-grade gliomas and suggests that GATA2 could be a potential biomarker for precision medicine approaches.

Background/Objectives: Lower-grade gliomas, particularly IDH-mutant astrocytomas, represent a distinct molecular subtype with unique therapeutic challenges. Whole-genome sequencing (WGS) plays a crucial role in uncovering genetic alterations that drive glioma pathogenesis and therapeutic resistance. This study identifies and evaluates a novel GATA2 p.Arg396Trp mutation in a clinical sample of lower-grade glioma, assessing its structural impact and implications for drug binding. Methods: A WHO Grade II astrocytoma specimen from a 33-year-old female patient was analyzed using WGS with Oxford Nanopore sequencing, followed by comprehensive bioinformatics processing to identify genomic variants. The GATA2 p.Arg396Trp mutation was evaluated using protein modeling, structural analysis, and pathogenicity prediction tools. Drug affinity analysis was conducted using molecular docking simulations to assess the computational impact of the mutation on drug binding. Results: The GATA2 p.Arg396Trp mutation was identified as a computationally predicted pathogenic variant, potentially disrupting protein interactions within critical functional domains. Structural analysis revealed altered binding dynamics with key anti-neoplastic agents, suggesting potential implications for therapeutic response. These findings represent computational predictions requiring experimental validation. Conclusions: Our preliminary findings suggest a potential role of the GATA2 p.Arg396Trp mutation in lower-grade glioma pathogenesis. The mutation predicted impact on transcriptional regulation and drug affinity suggests GATA2 as a possible biomarker candidate. Extensive experimental validation in larger patient cohorts is needed to establish clinical relevance and explore targeted therapeutic strategies.